Hologic (HOLX) appears to be having a busy time, reporting its quarter earnings, and participating in several key healthcare conferences. Despite some underperformance in the stock market, it's been generally attracting investor attention. The key highlights include the company's acquisition of
Gynesonics and
Endomagnetics Ltd., which hints at expansion and diversification of its portfolio. Several substantial transactions indicate heightened market activity around HOLX, with purchases by
JP Morgan Chase & Co., Diversified Trust Co, and Nordea Investment Management AB. Yet, First Hawaiian Bank sold a substantial number of shares. There were major changes at the board level with the inclusion of
Dr. Martin Madaus, diagnostic specialist and ex-CEO of Ortho Clinical. HOLX is slated to announce Q1 2025 results on February 5. On the downside, it closed a facility in Connecticut and faced several revenue challenges resulting in stock underperformance. Despite this, analysts give HOLX a 'Moderate Buy' rating.
Hologic HOLX News Analytics from Mon, 29 Apr 2024 07:00:00 GMT to Sat, 11 Jan 2025 09:08:20 GMT -
Rating -2
- Innovation 2
- Information 8
- Rumor -4
